Features of the treatment of elderly patients with coronary heart disease at the stages of 1990, 2010 and 2017 examinations.
DOI:
https://doi.org/10.26641/2307-0404.2018.4.152989Keywords:
coronary heart disease, elderly patients, features of treatmentAbstract
The purpose of the work is to determine the characteristics of prescription, adherence to treatment and the effect of certain classes of drugs used for the treatment of cardiovascular diseases on the life expectancy of elderly patients with ischemic heart disease (IHD). 517 case histories of patients aged 60-87 (–91) years old, born in 1925-1957 with IHD were analyzed. All the examined were first hospitalized in the hospital and later were observed with the main diagnosis of coronary artery disease: stable exertional angina I-IV FC. Further observation of the patients lasted from 3 to 25 years (average observation period 10 years), until reaching the endpoint or until the last observation in 2017. The patient’s death was chosen as the endpoint, on the basis of which the life expectancy index (determined by the year / age of death) was studied. It has been shown, that therapeutic regimens for the elderly patients with coronary artery disease meet current standards for the treatment of coronary artery disease at the stages of 1990, 2010 and 2017. Patients' adherence to therapy was 82.4%. According to the data obtained, the association of taking certain classes of drugs with the life expectancy of patients was: ACE inhibitors increase life expectancy by 7 years, acetylsalicylic acid (ASA) - by 4 years, statins and β-blockers - by 2 years. The most effective combinations for treating people with IHD that affect life expectancy are: combinations of ASC, statins and ACE inhibitors - survival up to 80.14±3.16 years, ASA, statins and Ca-channel blockers - survival up to 80±1.71 years, ASC, statins and β-blockers - survival to 79.3±4.24 years, ASA and ACE inhibitors - survival to 79.59±3.83 years.References
[Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis]. Recommendations VNOK.Moscow; 2005;9-14. Russian.
Sokolov MYu, Talaeva TV. [Prevention of cardiovascular diseases]. Adapted clinical guidance, based on evidence. 2016;8-111. Ukrainian.
Shalaev SV, KremnevаLV, Аbaturovа ОV. [Pulse reducing therapy of the chronic cardiac failure]. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2015;11(1):79-84 Russian.
ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation. 1998;97:2202-2211.
Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. 1995;332:80-85.
Pilotto A, Leandro G, Franceschi M, Di Mario F, Valerio G. Antagonism to calcium antagonists. Lancet. 1996;347:1761-2.
Antithrombotic Trialists'(ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009;373(9678):1849-60. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=19482214.
Ball S, Hall A, Murray G. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. J. Am. Coll. Cardiol. 1995;25;42-46.
Pahor M, Guralnik JM, Ferrucci L, Corti M-C, Salive ME, Cerhan J, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493-7.
Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817-822.
Califf RM, Granger CB. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). Diabetes Care. 1998;21:655-7.
Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens. 1985;3(4):379-92.
Gottlieb S, Leor J, Shotan A, Harpaz D, Boyko V, Rott D, et al. Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients. Am. J. Cardiol. 2003;92:1020-5.
Franzosi MG, Maggioni AP, Santoro E, et al. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics. 1998;13(3):337-46.
Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103(24):2949-54.
Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996;9:695-9.
Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT- LLT randomized clinical trial [published online May 22, 2017]. JAMA Intern Med. doi: 10.1001/jamainternmed.2017.1442.
Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-601.
Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-10.
Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
Epstein B, Vogel K, Palmer B. Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. Drugs 2007;67(9):1309-27.
Dickstein K, Cohen-Solal A, Filippatos G, et al. (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 10:933-89.
Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomised factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-85.
Fox KM. European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentrer trial (the EUROPA study). Lancet. 2003;362:782-8.
Francisco J Caballero-Gonzalez. Calcium Channel Blockers in the Management of Hypertension in the Elderly. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2014;12:(3):160-4.
Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation.1995;92:1326-31.
GISSI-3 Investigators GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343:1115-22.
Pedrazzini G, Santoro E, Latini R, et al. GISSI-3 Investigators Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)-3 trial. Am. Heart J. 2008;155(2):388-94.
GoaKL, Balfour JA, Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs. 1996;52(4):564-88.
Grossman E, Messerli F. Calcium Antagonists. Prog Cardiovasc Dis. 2004;47(1):34-47.
Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:1187-9.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-85.
Lane RE, Cowie MR, Chow AW. Prediction and prevention of sudden cardiac death in heart failure. Heart. 2005;91(5):674-80.
Pahor M, Guralnik JM, Corti M-C, Foley DJ, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 1995;43:1191-7.
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304:405-12.
Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903-7.
McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784-94.
National Institute for Health and Clinical Excellence. Clinical Guideline: Hypertension: Management of hypertension in adults in primary care. June 2006. Available from: http://www.nice.org.uk/nicemedia/pdf/HypertensionGuide.pdf Accessed October 2007.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-31.
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet. 2005;366:895-906.
Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000;35(3):592-9.
Richards M. The safety of short and long-acting calcium antagonists in the treatment of angina and hypertension. Therapeutic Notes. 1996;220.
Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik R. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:1061-5.
Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2007;62:879-87.
Ble A, Hughes PM, Delgado J, et al. Safety and effectiveness of statins for prevention of recurrent myocardial infarction in 12 156 typical older patients: a quasi-experimental study. J Gerontol A Biol Sci Med Sci. 2017;72:243-50.
Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinaviam Simvastatin Survival Study (4S). Lancet. 1994;344:1383-89.
Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med. 2013;173(14):1-10.
Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995;310:776-7.
Brugts JJ, Yetgin T, Hoeks S, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi: 10.1136/bmj.2376.
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. l998;338:645-52.
Daly C, Fox K, Remme W, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur. Heart J. 2005;26:1369-78.
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, et al. The risk of myocardial infarction associated with antihypertensive drug therap. JAMA. 1995;274:620-5.
Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA-II study. Eur J Heart Fail. 2006;8:302-7.
Lainscak M, Moullet C, Schön N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol. 2007;122:149-55.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/ EAS Guidelines for the Management of Dyslipidaemias: TheTask Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281-344.
Yusuf S, Held PH, Furberg CD. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-7.
Zanchetti A. The European Lacidipine Study on Atherosclerosis: Study desigh and results, in Eleventh European Meeting on Hypertention.Milan,Italy, June 2007;15-19.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
